Amarin Drug-Label Case Imperils Low-Cost Competition, Group Says

The generic drug industry is trying to stop a patent lawsuit it says will further endanger a routine labeling practice for providing low-cost treatment alternatives.

Amarin Pharma Inc.'s lawsuit to get Hikma Pharmaceuticals Inc.‘s generic version of its Vascepa heart drug off the shelves threatens “to make a dead letter” out of a long-used practice for bringing cheaper versions of drug products to the market, the Association for Accessible Medicines said in a Thursday brief.

“The ultimate victim of these misguided claims will be the American public, which will face higher prices for branded medicines that Congress intended to ...